Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial
Journal of Clinical Oncology · 10.03.2023 · 41 (8) · 1541-1552
DOI: 10.1200/jco.22.00046 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2023. Verfasst von Dion Morton und 13 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Birmingham, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Fluorouracil, Colonic Neoplasms. Die Arbeit wurde bisher 459-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation. METHODS Patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks postoperatively (control group). Patients with RAS-wildtype tumors could also be randomly assigned 1:1 to receive panitumumab or not during NAC. The primary end point was residual disease or recurrence within 2 years. Secondary outcomes included surgical morbidity, histopathologic stage, regression grade, completeness of resection, and cause-specific mortality. Log-rank analyses were by intention-to-treat. RESULTS Of 699 patients allocated to NAC, 674 (96%) started and 606 (87%) completed NAC. In total, 686 of 699 (98.1%) NAC patients and 351 of 354 (99.2%) control patients underwent surgery. Thirty patients (4.3%) allocated to NAC developed obstructive symptoms requiring expedited surgery, but there were fewer serious postoperative complications with NAC than with control. NAC produced marked T and N downstaging and histologic tumor regression (all P < .001). Resection was more often histopathologically complete: 94% (648/686) versus 89% (311/351), P < .001. Fewer NAC than control patients had residual or recurrent disease within 2 years (16.9% [118/699] v 21.5% [76/354]; rate ratio, 0.72 [95% CI, 0.54 to 0.98]; P = .037). Tumor regression correlated strongly with freedom from recurrence. Panitumumab did not enhance the benefit from NAC. Little benefit from NAC was seen in mismatch repair–deficient tumors. CONCLUSION Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy for operable colon cancer can be delivered safely, without increasing perioperative morbidity. This chemotherapy regimen, when given preoperatively, produces marked histopathologic down-staging, fewer incomplete resections, and better 2-year disease control. Histologic regression after NAC is a strong predictor of lower postoperative recurrence risk so has potential use as a guide for postoperative therapy. Six weeks of NAC should be considered as a treatment option for locally advanced colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Birmingham, Birmingham, United Kingdom.
- St James's University Hospital, Leeds, United Kingdom.
- University of Birmingham Clinical Trials Unit, Birmingham, United Kingdom.
- Uppsala University, Uppsala, Sweden.
- Aarhus University, Aarhus, Denmark.
- Division of Pathology and Data Analytics, School of Medicine, University of Leeds, Leeds, United Kingdom.
ORCID-Profile: Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Jenny Seligmann, Keigo Murakami, Nick West, Philip Quirke, Richard Gray
Förderung
- Cancer Research UK
Zitieren
APA
Morton, D., Seymour, M., Magill, L., Handley, K., Glasbey, J., Glimelius, B., Palmer, A., Seligmann, J., Laurberg, S., Murakami, K., West, N., Quirke, P., Gray, R., & FOxTROT Collaborative Group (2023). Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. Journal of Clinical Oncology, 41(8), 1541-1552. https://doi.org/10.1200/jco.22.00046
Vancouver
Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. Journal of Clinical Oncology. 2023;41(8):1541-1552. doi:10.1200/jco.22.00046
BibTeX
@article{Morton2023,
author = {Morton, Dion and Seymour, Matthew and Magill, Laura and Handley, Kelly and Glasbey, James and Glimelius, Bengt and Palmer, Andy and Seligmann, Jenny and Laurberg, Søren and Murakami, Keigo and West, Nick and Quirke, Philip and Gray, Richard and FOxTROT Collaborative Group, FOxTROT Collaborative Group},
title = {Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {8},
pages = {1541--1552},
doi = {10.1200/jco.22.00046}
}
EUVIMED